Pulmonary pharmacokinetics and lesion penetration of antimicrobials in patients with nontuberculous mycobacterial disease. (PubMed, Antimicrob Agents Chemother) - Oct 2, 2026 - "This study characterized the plasma and intrapulmonary pharmacokinetics of azithromycin, ethambutol, rifampicin, clofazimine, and amikacin, as well as their penetration into pulmonary lesion sites. The intrapulmonary pharmacokinetic characteristics identified in this study provide valuable information for optimizing antimicrobial dosing regimens in the treatment of NTM pulmonary disease. Furthermore, the absence of clearly reduced drug penetration into lesion sites suggests that lesion phenotype alone may have limited value in guiding antimicrobial selection."
Journal • PK/PD data • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases
|
|
Fumiya Watanabe; Hayato Nanami; Kazuhiko Hanada; Kiyomi Shimoda; Kozo Morimoto; Miyako Hiramatsu; Teruaki Oka; Toru Kawakami; Yuji Shiraishi
|